Davis Investment Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.49M Buy
1,243
+37
+3% +$37.8K 0.45% 40
2026
Q1
$1.11M Buy
1,206
+13
+1% +$13.2K 0.39% 45
2025
Q4
$1.29M Buy
1,193
+102
+9% +$97.5K 0.45% 45
2025
Q3
$901K Hold
1,091
0.31% 50
2025
Q2
$847K Sell
1,091
-32
-3% -$24.9K 0.3% 53
2025
Q1
$847K Buy
1,123
+62
+6% +$51.6K 0.37% 49
2024
Q4
$849K Buy
1,061
+204
+24% +$169K 0.36% 52
2024
Q3
$763K Sell
857
-47
-5% -$42.3K 0.32% 60
2024
Q2
$857K Buy
904
+70
+8% +$56K 0.35% 56
2024
Q1
$636K Buy
+834
New +$594K 0.28% 66

Other funds holding LLY

Davis Investment Partners's LLY Position: Q2 2026 in Review

Davis Investment Partners increased its Eli Lilly (LLY) stake by 3.1% in Q2 2026, buying an estimated $37.8K and bringing the position to 1,243 shares worth $1.49M. The position accounts for 0.45% of the portfolio, ranked #40.

Davis Investment Partners first reported a position in LLY in Q1 2024 and has held it in 10 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Davis Investment Partners held 1,243 shares of Eli Lilly worth $1.49M as of Q2 2026.
  • Davis Investment Partners bought 37 Eli Lilly shares in Q2 2026, an estimated $37.8K.
  • Eli Lilly made up 0.45% of Davis Investment Partners's portfolio in Q2 2026, its #40 holding.
  • Davis Investment Partners first reported a position in Eli Lilly in Q1 2024 and has held it in 10 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Davis Investment Partners's 13F filing for Q2 2026, filed 7 Aug 2026.